USFDA Clearance For Pre Approval Inspection At Ahmedabad Site

21 Apr 2026 CW Team

The organisation submitted the notice in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and asked that the information be brought to the attention of members of the exchange and the investing public. The disclosure highlighted the receipt of the Establishment Inspection Report, commonly abbreviated to EIR, and the approval letter for the Pre-Approval Inspection, commonly abbreviated to PAI.

The SEZ oncology injectable manufacturing site, hereafter the site, will be referenced by its acronym in subsequent communications. The company indicated that the inspection related specifically to the newly authorised isolator injectable line and provided the dates of the audit for record and compliance purposes. The disclosure did not include further operational detail beyond the scope of the inspection report and approval. The company said existing quality systems will govern the integration of the new line into routine operations and timely reporting.

Regulatory acknowledgement from the USFDA for the PAI represents a procedural milestone in the company's efforts to finalise commissioning of the line, the company added. The organisation confirmed it will adhere to listing and disclosure norms and will update stakeholders as appropriate through established channels. The company noted that regulatory records and correspondence will be maintained for audit and compliance purposes. Stakeholder communications will be issued through official regulatory filings and stock exchange disclosures.

The company has received the Establishment Inspection Report and an approval letter from the United States Food and Drug Administration (USFDA) following a Pre-Approval Inspection at its special economic zone (SEZ) oncology injectable manufacturing facility in SEZ1, Ahmedabad. The clearance relates to a new isolator injectable line and was disclosed in a filing dated 16 April, 2026. The inspection took place from fourth to 13th November, 2025 and resulted in documentation that the company said it had received. The organisation submitted the notice in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and asked that the information be brought to the attention of members of the exchange and the investing public. The disclosure highlighted the receipt of the Establishment Inspection Report, commonly abbreviated to EIR, and the approval letter for the Pre-Approval Inspection, commonly abbreviated to PAI. The SEZ oncology injectable manufacturing site, hereafter the site, will be referenced by its acronym in subsequent communications. The company indicated that the inspection related specifically to the newly authorised isolator injectable line and provided the dates of the audit for record and compliance purposes. The disclosure did not include further operational detail beyond the scope of the inspection report and approval. The company said existing quality systems will govern the integration of the new line into routine operations and timely reporting. Regulatory acknowledgement from the USFDA for the PAI represents a procedural milestone in the company's efforts to finalise commissioning of the line, the company added. The organisation confirmed it will adhere to listing and disclosure norms and will update stakeholders as appropriate through established channels. The company noted that regulatory records and correspondence will be maintained for audit and compliance purposes. Stakeholder communications will be issued through official regulatory filings and stock exchange disclosures.

Infrastructure Urban

21 Apr 2026

Leaders Question FIR Against Anil Agarwal

Several industry and public figures have questioned the FIR filed against Anil Agarwal following the boiler accident in Chhattisgarh, while also expressing condolences over the loss of lives and calling for a thorough investigation.Naveen Jindal said the tragedy was deeply painful and stressed that compensation, livelihood support for affected families and a fair probe were essential. He also questioned naming Agarwal in the FIR before completion of the investigation.Kiran Bedi urged restraint, saying investigations should focus on learning lessons and strengthening systems rather than prematu..

Infrastructure Urban

21 Apr 2026

Tier 2, 3 Cities Drive 66% of New D2C Orders

Tier 2 and Tier 3 cities accounted for 66 per cent of new direct-to-consumer (D2C) orders in FY 2026, according to a new analysis by Unicommerce.The report said buyers from smaller cities also contributed 60 per cent of incremental gross merchandise value (GMV) in FY 2026 compared with FY 2025, highlighting rising demand beyond metro markets.Overall, India’s D2C segment recorded strong growth, with order volumes rising 33 per cent and GMV increasing 32 per cent year-on-year. The findings are based on more than 400 million order items processed through brand websites on Unicommerce’s Uniwar..

Infrastructure Urban

21 Apr 2026

Chola Securities Gives Buy Call on Aadhar Housing

Chola Securities has initiated a buy call on Aadhar Housing Finance, projecting an upside potential of 24.8 per cent over a 15–18 month period.The brokerage cited the company’s steady business growth, with assets under management (AUM) rising at about 20 per cent CAGR between FY22 and FY25, while maintaining a similar year-on-year growth rate in 9MFY26. AUM increased from Rs 13,327 crore in FY21 to Rs 25,531 crore in FY25, and further to Rs 28,790 crore in 9MFY26.Chola Securities also highlighted the company’s asset quality, with gross NPAs at 1.40 per cent and net NPAs at 1.0 per cent, ..